European Journal of Cancer
Volume 39, Issue 7 , Pages 917-926 , May 2003

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

  • F.A.L.M Eskens

      Affiliations

    • Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-10-463-4897; fax: +31-10-463-4627
    • ,
  • H Dumez

      Affiliations

    • University Hospital Gasthuisberg, 3000 Leuven, Belgium
    • ,
  • R Hoekstra

      Affiliations

    • Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • A Perschl

      Affiliations

    • Merck KGaA, D-64293 Darmstadt, Germany
    • ,
  • C Brindley

      Affiliations

    • Quintiles Scotland Limited, Edinburgh EH14 4AP, Scotland, UK
    • ,
  • S Böttcher

      Affiliations

    • Merck KGaA, D-64293 Darmstadt, Germany
    • ,
  • W Wynendaele

      Affiliations

    • University Hospital Gasthuisberg, 3000 Leuven, Belgium
    • ,
  • J Drevs

      Affiliations

    • Tumour Biology Center, Freiburg, Germany
    • ,
  • J Verweij

      Affiliations

    • Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • A.T van Oosterom

      Affiliations

    • University Hospital Gasthuisberg, 3000 Leuven, Belgium

Received 4 July 2002 ,Accepted 21 November 2002.

References 

  1. Cherish D. Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and Van Willebrand factor. Proc Natl Acad Sci USA. 1987;84:6471–6475
  2. Cheresh D. Integrins (structure, function and biological properties). Adv Mol Cell Biol. 1993;6:225–252
  3. Varner JA, Brooks PC, Cheresh DA. Review (the integrin αvβ3: angiogenesis and apoptosis). Cell Adhes Comm. 1995;3:367–374
  4. Max R, Gerritsen RRCM, Nooijen PTGA, et al.  Immunohistochemical analysis of integrin αvβ3 expression on tumour-associated vessels of human carcinomas. Int J Cancer. 1997;71:320–324
  5. Brooks PC, Clarke RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994;264:569–571
  6. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science. 1995;270:1500–1502
  7. Li X, Chen B, Blystone SD, McHugh KP, Ross FP, Ramos DM. Differential expression of αv integrins in K1735 melanoma cells. Invasion Metastasis. 1998;18:1–14
  8. Friedlander M, Theesfeld CL, Sugita M, et al.  Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 1996;93:9764–9769
  9. Gasparini G, Brooks PC, Biganzoli E, et al.  Vascular integrin αvβ3 (a new prognostic indicator in breast cancer). Clin Cancer Res. 1998;4:2625–2634
  10. National Cancer Institute . Guidelines for Reporting of Adverse Drug Reactions. Bethesda: Division of cancer treatment, National Cancer Institute; 1988;
  11. World Health Organization . WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 40. Geneva, Switzerland: WHO; 1979;
  12. Gough K, Hutchison M, Keene O. Assessment of dose proportionality (report from the statisticians in the pharmaceutical industry/Pharmacokinetics UK joint working party). Drug Inform J. 1995;29:1039–1048
  13. Peters KG, Coogan A, Berry D, et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 1998;77:51–56
  14. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY. Angiopoeitin-1 and its receptor Tie-2 participate in the regulation of capillary-like tube formation and survival of endothelial cells. Microvasc Res. 1999;58:224–237
  15. Hebbar M, Revillion F, Louchez MM, Fournier C, Bonneterre J, Peyrat JP. Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients. Clin Cancer Res. 1999;5:1427–1433
  16. Wynendaele W, Derua R, Hoylaerts MF, et al.  Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers (a key to study an angiogenic marker in vivo?). Ann Oncol. 1999;10:965–971
  17. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marme D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase (FLT-1) and a soluble form of FLT-1 in human vascular endothelial cells. Cancer Res. 1997;57:5421–5425
  18. Cutler NR, Sramek JJ, Greenblatt DJ, Chaikin P, Collins J. Defining the maximum tolerated dose (an update). J Clin Pharmacol. 2000;40:1183–1204
  19. Arbuck SG. Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol. 1996;7:567–573
  20. Gutheil JC, Campbell TN, Pierce PR, et al.  Targeted antiangiogenic therapy for cancer using Vitaxin (a humanized monoclonal antibody to the integrin αvβ3). Clin Cancer Res. 2000;6:3056–3061
  21. Eskens FALM, Verweij J. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models (facing the challenge of a proper study design). Crit Rev Oncol Hematol. 2000;34:83–88
  22. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment (challenges for drug development?). J Natl Cancer Inst. 1999;91:1281–1287
  23. Gordon MS, Margolin K, Talpaz M, et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843–850
  24. Margolin K, Gordon MS, Holmgren E, et al.  Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer (pharmacologic and long-term safety data). J Clin Oncol. 2001;19:851–856

PII: S0959-8049(03)00057-1

doi: 10.1016/S0959-8049(03)00057-1

European Journal of Cancer
Volume 39, Issue 7 , Pages 917-926 , May 2003

Article Tools

* Image Usage & Resolution